Get started
Author

Ricardo Ramirez

Observed institution: Sapience Therapeutics
ORCID: 0000-0003-3453-6164
Observed ORCID: 0000-0003-3453-6164
OpenAlex ID: A5029317866
Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2022 · Emad Darvishi, Lila Ghamsari, et al. · Molecular Cancer Therapeutics · 22
PDF
Abstract 5332: ST316, a clinical peptide antagonist of beta-catenin, induces anti-tumor immune responses by multiple mechanisms of action
2024 · Claudio Scuoppo, Karen Mendelson, et al. · Cancer Research · 3
1451 ST316, a peptide antagonist of β-Catenin, depletes immunosuppressive myeloid cell populations and enhances anti-cancer immune responses in in vivo tumor models and in patients
2024 · Claudio Scuoppo, Ricardo Ramirez, et al. · Journal for ImmunoTherapy of Cancer · 1
Abstract 4767: Targeted antagonism of the activator protein 1 transcription factor complex results in potent anti-tumor activity in HNSCC models
2026 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
1198 Antagonism of beta-catenin/Bcl9 impairs generation of immune-suppressive MDSCs and promotes enhanced immune responses
2025 · Claudio Scuoppo, Julia Diehl, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 839: The clinical C/EBPβ antagonist peptide lucicebtide synergizes with molecularly targeted therapies in GBM
2025 · Julia Diehl, Ricardo Ramirez, et al. · Cancer Research
Abstract 1415: FraAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in HNSCC models
2025 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
Abstract 3275: Reprogramming of MDSCs by ST316, a clinical peptide antagonist of b-Catenin/BCL9, enhances anti-tumor immuno- and chemotherapy
2025 · Claudio Scuoppo, Julia Diehl, et al. · Cancer Research
Abstract 2909: ST101, a clinical CEBPβ antagonist peptide, promotes an immune-active tumor microenvironment by multiple cellular mechanisms
2024 · Claudio Scuoppo, Julia Diehl, et al. · Cancer Research
Abstract 3051: JunAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in TNBC models
2024 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
Supplementary Table from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Supplementary Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Supplementary Table from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Supplementary Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Works count: 16
Citation count: 26
H-index: 2
I10-index: 1
Year
Topic
Type